Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 287

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 287
---
Note 7)

    Stockholders’ equity:

    Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 101,116,162 and 87,227,132 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively

    10

    9

    Additional paid-in-capital

    1,056,738

    805,107

    Accumulated other comprehensive income

    84

    9

    Accumulated deficit

    (554,081
    )

    (458,585
    )

    Total stockholders’ equity

    502,751

    346,540

    Total liabilities and stockholders' equity
     
    $
    582,788

    $
    376,048

The accompanying notes are an integral part of these financial statements.

F-6

Day One Biopharmaceuticals, Inc. 

Statements of Operations

(in thousands, except share and per share amounts)

    Year Ended December 31,

    2024

    2023

    2022

    Revenue:

    Product revenue, net
     
    $
    57,217

    $
    —

    $
    —

    License revenue

    73,944

    —

    —

    Total revenues

    131,161

    —

    —

    Cost and operating expenses:

    Cost of product revenue

    5,279

    —

    —

    Research and development

    227,702

    130,521

    85,618

    Selling, general and administrative

    115,450

    75,543

    61,291

    Total cost and operating expenses

    348,431

    206,064

    146,909

    Loss from operations

    (217,270
    )

    (206,064
    )

    (146,909
    )

    Non-operating income:

    Gain from sale of priority review voucher

    108,000

    —

    —

    Investment income, net

    19,701

    17,187

    4,746

    Other income (expense), net

    1,217

    (40
    )

    (